Information Provided By:
Fly News Breaks for March 3, 2020
ALNY
Mar 3, 2020 | 10:47 EDT
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $155 price target on Alnylam after the company announced that the approved GIVLAARI to treat acute hepatic porphyrias in adults and adolescents 12 years and older. In a research note to investors, Tenthoff forecast U.S. and European GIVLAARI sales of $12M this year and says ONPATTRO continues to grow from $166M in 2019 to management guidance of $285M-$315M this year.
News For ALNY From the Last 2 Days
There are no results for your query ALNY